Sonali M. Smith, MD

Sonali M. Smith, MD, is the holder of the Elwood V. Jensen Professorship of Medicine and chief of the Section of Hematology/Oncology at University of Chicago Medicine.

Articles by Sonali M. Smith, MD

Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.

Dr Smith on Implications of Data From the frontMIND Trial in DLBCL

BySonali M. Smith, MD

June 9th 2026

Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.

Unmet Needs and Future Directions in Care in CLL

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 8th 2023

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 8th 2023

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 1st 2023

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

March 1st 2023

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan O’Brien, MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 22nd 2023

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 22nd 2023

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 15th 2023

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 15th 2023

Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 8th 2023

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 8th 2023

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.

Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 1st 2023

Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

February 1st 2023

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 25th 2023

Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 25th 2023

Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 18th 2023

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.

Brief Overview of Chronic Lymphocytic Leukemia

BySonali M. Smith, MD,Nicole Lamanna, MD,Susan M. O'Brien MD,Sameer Parikh, MD,Ryan W. Jacobs, MD,John Allan, MD

January 18th 2023

Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.

Dr. Smith on Unmet Clinical Needs in Indolent Lymphomas

BySonali M. Smith, MD

May 21st 2020

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Dr. Smith on Unmet Clinical Needs in Indolent Lymphomas

BySonali M. Smith, MD

May 21st 2020

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

BySonali M. Smith, MD

May 18th 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

BySonali M. Smith, MD

May 18th 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Dr. Smith on Frontline Treatment Options in MCL

BySonali M. Smith, MD

May 13th 2020

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Dr. Smith on Frontline Treatment Options in MCL

BySonali M. Smith, MD

May 13th 2020

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Dr. Smith on Safety Profiles of BTK Inhibitors in MCL

BySonali M. Smith, MD

May 11th 2020

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Dr. Smith on the Guiding Principles for Treating iNHL

BySonali M. Smith, MD

February 29th 2020

Sonali M. Smith, MD, discusses the prognosis of patients with indolent non-Hodgkin lymphomas.

Dr. Smith Advises Clinicians on Diagnosing Double-Hit and Triplet-Hit Lymphoma

BySonali M. Smith, MD

September 5th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Dr. Smith Discusses the Diagnosis of Double-Hit Lymphoma

BySonali M. Smith, MD

August 17th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the diagnosis of double-hit lymphoma.

Dr. Smith Discusses Double-Hit and Triple-Hit Lymphoma

BySonali M. Smith, MD

July 30th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses double-hit and triple-hit lymphoma.

Dr. Smith Discusses Brentuximab Vedotin in CTCL

BySonali M. Smith, MD

July 20th 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma.